Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, W.
Right arrow Articles by Howard, B. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, W.
Right arrow Articles by Howard, B. V.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 25:1365-1370, 2002
© 2002 by the American Diabetes Association, Inc.


Epidemiology/Health Services/Psychosocial Research
Original Article

Using HbA1c to Improve Efficacy of the American Diabetes Association Fasting Plasma Glucose Criterion in Screening for New Type 2 Diabetes in American Indians

The Strong Heart Study

Wenyu Wang, PHD1, Elisa T. Lee, PHD1, Richard Fabsitz, MA2, Thomas K. Welty, MD, MPH3 and Barbara V. Howard, PHD4

1 College of Public Health, University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma
2 National Heart, Lung and Blood Institute, Bethesda, Maryland
3 Aberdeen Area Tribal Chairmen’s Health Board, Aberdeen, South Dakota
4 Medlantic Research Institute, Washington, DC

OBJECTIVE—To find an optimal critical line in the fasting plasma glucose (FPG)-HbA1c plane for identifying diabetes in participants with impaired fasting glucose (IFG) and thereby improve the efficacy of using FPG alone in diabetes screening among American Indians.

RESEARCH DESIGN AND METHODS—We used FPG, 2-h postload glucose (2hPG), and HbA1c measured in the 2,389 American Indians (aged 45–74 years, without diabetes treatment or prior history of diabetes) in the Strong Heart Study (SHS) baseline (second) examination. Participants were classified as having diabetes if they had either FPG >=126 mg/dl or 2hPG >=200 mg/dl, as having IFG if they had 110 <= FPG < 126 mg/dl, and as having normal fasting glucose (NFG) if they had FPG <110, according to the American Diabetes Association (ADA) definition. Logistic regression models were used for identifying diabetes (2hPG >=200 mg/dl) in IFG participants. The areas under the receiver operating characteristic (ROC) curves generated by different logistic regression models were evaluated and compared to select the best model. A utility function based on the best model and the cost-to-benefit ratio was used to find the optimal critical line. The data from the second examination were used to study the effect of the time interval between the successive diabetes screenings on both the FPG criterion and the optimal critical line.

RESULTS—A total of 37% of all subjects with new diabetes at baseline and 55.2% of those in the second exam had 2hPG >=200 but FPG <126. There was a very large portion of IFG participants with diabetes (19.3 and 22.9% in the baseline and second exam, respectively). Among the areas under the ROC curves, the area generated by the logistic regression model on FPG plus HbA1c is the largest and is significantly larger than that based on FPG (P = 0.0008). For a cost-to-benefit ratio of 0.23888, the optimal critical line that has the highest utility is: 0.89 x HbA1c + 0.11 x FPG = 17.92. Those IFG participants whose FPG and HbA1c were above or on the line were referred to take an oral glucose tolerance test (OGTT) to diagnose diabetes. The optimal critical line is lower if a successive diabetes screening will be conducted 4 years after the previous screening.

CONCLUSIONS—FPG >=126 and 2hPG >=200, as suggested by the ADA, are used independently to define diabetes. The FPG level is easy to obtain, and using FPG alone is suggested for diabetes screening. It is difficult to get physicians and patients to perform an OGTT to get a 2hPG level because of the many drawbacks of the OGTT, especially in those patients who already have FPG <126. It is also impractical to conduct an OGTT for everyone in a diabetes screening. Our data show that 37% of all subjects with new diabetes in the SHS baseline exam and 55.2% of those in the second exam have 2hPG >=200 but FPG <126. These cases of diabetes cannot be detected if FPG is used alone in a diabetes screening. Therefore, although the small portion of diabetes in the NFG group (4.7% in the baseline and 6.9% in the second exam) may be ignored, those cases of diabetes among IFG participants (~20% in our data) need further consideration in a diabetes screening. It may be worthwhile for those IFG participants identified by the optimal critical line to take an OGTT. The optimal critical line and time interval between successive diabetes screenings need further study.

Abbreviations: 2hPG, 2-h postload glucose • ADA, American Diabetes Association • FPG, fasting plasma glucose • 2hPG, IFG, impaired fasting glucose • INNSZ, Instituto Nacional de la Nutricion Salvador Zubiran • NFG, normal fasting glucose • OGTT, oral glucose tolerance test • ROC, receiver operating characteristic • SHS, Strong Heart Study


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
S. Genuth and R. Kahn
A Step Backward--or Is it Forward?
Diabetes Care, June 1, 2008; 31(6): 1093 - 1096.
[Full Text] [PDF]


Home page
HypertensionHome page
W. Wang, E. T. Lee, R. R. Fabsitz, R. Devereux, L. Best, T. K. Welty, and B. V. Howard
A Longitudinal Study of Hypertension Risk Factors and Their Relation to Cardiovascular Disease: The Strong Heart Study
Hypertension, March 1, 2006; 47(3): 403 - 409.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
Expert Committee on the Diagnosis and Classificati
Follow-up Report on the Diagnosis of Diabetes Mellitus
Clin. Diabetes, April 1, 2004; 22(2): 71 - 79.
[Full Text] [PDF]


Home page
Br. J. PsychiatryHome page
S. Gough and R. Peveler
Diabetes and its prevention: pragmatic solutions for people with schizophrenia
The British Journal of Psychiatry, April 1, 2004; 184(47): s106 - s111.
[Abstract] [Full Text] [PDF]


Home page
Diabetes Spectr.Home page
Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Spectr, January 1, 2004; 17(1): 51 - 59.
[Full Text] [PDF]


Home page
Diabetes CareHome page
The Expert Committee on the Diagnosis and Classifi
Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Care, November 1, 2003; 26(11): 3160 - 3167.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.